H.C. Wainwright keeps Buy, USD 8.00 Prelude target
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
H.C. Wainwright reiterated its Buy rating and USD 8.00 price target on Prelude Therapeutics after the company struck a collaboration with Eli Lilly for a Phase 1 breast cancer trial. The deal gives Prelude access to Lilly's drugs for combination cohorts testing PRT13722, an oral KAT6A selective degrader, with patient enrollment expected in Q4 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.